Exploring Arcutis Biotherapeutics, Inc. (ARQT) Investor Profile: Who’s Buying and Why?

Have you been keeping an eye on Arcutis Biotherapeutics, Inc. (ARQT) and wondering who's investing and why? With a keen focus on immuno-dermatology, Arcutis has shown significant financial strides, reporting a 413% year-over-year increase in Q4 2024 net product revenue, reaching $69.4 million, and a full-year revenue of $166.5 million, a 471% increase from 2023. But who are the major players backing this growth, and what makes them so confident in Arcutis's trajectory? Is it the potential 44.50% upside from the latest price, as suggested by analysts with a 'Strong Buy' consensus, or the impressive revenue growth and market penetration of ZORYVE® across multiple indications? Let's delve into the investor profile of Arcutis Biotherapeutics to uncover the motivations behind their investments.

Arcutis Biotherapeutics, Inc. (ARQT) Who Invests in Arcutis Biotherapeutics, Inc. (ARQT) and Why?

Understanding the investor profile of Arcutis Biotherapeutics, Inc. (ARQT) involves examining the diverse range of individuals and institutions that hold its stock, along with their motivations and strategies. This insight is crucial for current and prospective investors, as it sheds light on the market's sentiment and the factors driving the stock's performance.

Key Investor Types:

Arcutis Biotherapeutics, Inc. (ARQT) attracts a mix of investor types, each with their own investment horizon and risk tolerance:

• Retail Investors: Individual investors who buy and sell shares for their own accounts. Their investment decisions are often influenced by factors such as news, market trends, and personal financial goals.
• Institutional Investors: These include entities such as mutual funds, pension funds, and insurance companies. They typically manage large sums of money and conduct extensive research before investing.
• Hedge Funds: Actively managed investment funds that use a variety of strategies to generate returns. They may invest in Arcutis Biotherapeutics, Inc. (ARQT) based on specific market opportunities or events.

Investment Motivations:

Investors are drawn to Arcutis Biotherapeutics, Inc. (ARQT) for several reasons:

• Growth Prospects: The biotechnology sector offers significant growth potential, particularly for companies developing innovative therapies. Investors may be optimistic about Arcutis Biotherapeutics, Inc. (ARQT)'s pipeline and its ability to bring new products to market.
• Market Position: Arcutis Biotherapeutics, Inc. (ARQT)'s position within the dermatology market, focusing on innovative treatments for immune-mediated skin diseases, may attract investors seeking exposure to this specialized area.

Investment Strategies:

The strategies employed by Arcutis Biotherapeutics, Inc. (ARQT) investors vary depending on their investment goals and risk appetite:

• Long-Term Holding: Some investors adopt a buy-and-hold strategy, believing in the company's long-term potential and holding the stock for an extended period.
• Short-Term Trading: Other investors engage in short-term trading, seeking to profit from short-term price fluctuations in the stock.
• Value Investing: Value investors look for companies that they believe are undervalued by the market. They may invest in Arcutis Biotherapeutics, Inc. (ARQT) if they believe the stock price does not reflect the company's intrinsic value.

To provide a clearer picture, a breakdown of institutional ownership can offer insight into the types of firms that are invested in Arcutis Biotherapeutics, Inc. (ARQT). While specific, real-time data on individual holdings fluctuates, examining overall trends in institutional ownership can be beneficial.

Here’s a hypothetical example of what a snapshot of institutional ownership might reveal:

Understanding the composition and strategies of Arcutis Biotherapeutics, Inc. (ARQT)'s investor base is essential for assessing the stock's potential and making informed investment decisions. The blend of retail, institutional, and strategic investors contributes to the overall dynamics of the stock.

More information about Arcutis Biotherapeutics, Inc. (ARQT) can be found here: Mission Statement, Vision, & Core Values of Arcutis Biotherapeutics, Inc. (ARQT).

Arcutis Biotherapeutics, Inc. (ARQT) Institutional Ownership and Major Shareholders of Arcutis Biotherapeutics, Inc. (ARQT)

Institutional ownership in Arcutis Biotherapeutics, Inc. (ARQT) provides insights into the confidence and investment strategies of large financial entities. These major players can significantly influence the company’s stock performance and strategic direction. Understanding the profiles and activities of these investors is crucial for current and prospective shareholders.

Here's an overview, based on the latest available information, regarding the top institutional investors in Arcutis Biotherapeutics, Inc. (ARQT), changes in their ownership, and the potential impact they have on the company.

Top Institutional Investors:

As of Q1 2024, the top institutional holders of Arcutis Biotherapeutics, Inc. (ARQT) include:

• Vanguard Group Inc: Holding approximately 11.2 million shares, representing about 12.7% ownership.
• BlackRock Fund Advisors: Holding around 6.5 million shares, accounting for roughly 7.4% ownership.
• State Street Global Advisors: With approximately 3.2 million shares, holding about 3.6% ownership.
• RA Capital Management, L.P.: Holding approximately 3.1 million shares, accounting for roughly 3.5% ownership.
• FMR LLC: Holding around 2.9 million shares, accounting for roughly 3.3% ownership.

These institutional giants collectively hold a significant portion of Arcutis Biotherapeutics, Inc. (ARQT), reflecting their substantial interest in the company’s potential and performance.

Changes in Ownership:

Recent data indicates shifts in institutional ownership, reflecting evolving sentiments and strategic realignments:

• RA Capital Management, L.P.: Significantly increased its holdings by 14% in Q1 2024, adding 381,479 shares.
• Point72 Asset Management, L.P.: Also, significantly increased its holdings by 162% in Q1 2024, adding 358,038 shares.
• Vanguard Group Inc: decreased its holdings by 4% in Q1 2024, selling 484,715 shares.
• BlackRock Fund Advisors: decreased its holdings by 1% in Q1 2024, selling 72,140 shares.

These changes suggest active portfolio management among key institutional investors, potentially driven by factors such as Arcutis Biotherapeutics, Inc. (ARQT)’s clinical trial outcomes, market conditions, and overall financial performance.

Impact of Institutional Investors:

The substantial stakes held by institutional investors can significantly influence Arcutis Biotherapeutics, Inc. (ARQT)’s stock price and corporate strategy:

• Stock Price Stability: Large institutional holdings can provide a degree of stability to the stock price, as these investors typically make decisions based on long-term fundamentals.
• Corporate Governance: With significant voting power, institutional investors can influence corporate governance decisions, including executive compensation, board composition, and strategic direction.
• Market Confidence: Increased holdings by reputable institutions can signal positive market sentiment, attracting further investment and potentially driving up the stock price.
• Strategic Influence: Institutional investors often engage with company management to provide insights and feedback on strategic initiatives, influencing the company’s approach to research and development, market expansion, and financial management.

Here is a table summarizing key institutional ownership data for Arcutis Biotherapeutics, Inc. (ARQT):

Understanding these dynamics helps investors gauge market sentiment and the potential trajectory of Arcutis Biotherapeutics, Inc. (ARQT). For more insights into the company's strategic direction, explore Mission Statement, Vision, & Core Values of Arcutis Biotherapeutics, Inc. (ARQT).

Arcutis Biotherapeutics, Inc. (ARQT) Key Investors and Their Impact on Arcutis Biotherapeutics, Inc. (ARQT)

Understanding the investor profile of Arcutis Biotherapeutics, Inc. (ARQT) provides valuable insights into the company's stability, growth potential, and market sentiment. Examining who is investing and their recent activities can reveal important factors influencing the stock's performance and strategic direction. Here’s a detailed look at notable investors and their impact on Arcutis Biotherapeutics, Inc. (ARQT).

Institutional investors often hold significant stakes in biotech companies like Arcutis Biotherapeutics, Inc. (ARQT). These firms conduct extensive research before investing, and their actions can significantly influence stock prices. Key institutional holders may include:

• Vanguard Group: Known for its large index funds and long-term investment strategies.
• BlackRock Fund Advisors: Another major asset manager with substantial holdings across various sectors.
• State Street Corp: A leading provider of financial services to institutional investors.

These institutional investors typically have a long-term investment horizon, which can provide stability for Arcutis Biotherapeutics, Inc. (ARQT). Their decisions to increase or decrease their positions can signal confidence or concern about the company's prospects.

Hedge funds can also play a crucial role in Arcutis Biotherapeutics, Inc. (ARQT)'s investor landscape. These funds often take more active positions and may influence company decisions through activist strategies. Keep an eye on funds known for healthcare investments, as they may have specific insights into Arcutis Biotherapeutics, Inc. (ARQT)'s potential.

Individual insiders, such as executives and board members, are required to report their transactions in the company's stock. These transactions can offer valuable signals about the company’s internal outlook. For example, if several executives are buying shares, it could indicate strong confidence in the company's future. Conversely, significant selling by insiders might raise concerns.

Monitoring recent moves by major investors can provide clues about the changing sentiment surrounding Arcutis Biotherapeutics, Inc. (ARQT). Examples of notable moves include:

• Significant Buying: A large purchase of shares by a well-known fund can drive up the stock price and attract other investors.
• Significant Selling: Conversely, a major sell-off can create downward pressure on the stock.
• Activist Interventions: An activist investor taking a large stake and pushing for strategic changes can lead to significant shifts in company policy and stock performance.

To illustrate the kind of information that might be tracked, consider the following hypothetical snapshot of investor activity (please note this is an example and not actual data):

Changes in investor holdings can influence Arcutis Biotherapeutics, Inc. (ARQT)’s stock price. Increased institutional ownership typically reduces volatility, while activist interventions can create short-term price swings. Understanding these dynamics helps investors anticipate potential market reactions.

Large investors can influence company decisions through voting rights and direct engagement with management. Activist investors may propose specific changes, such as cost-cutting measures, strategic realignments, or even a sale of the company. Monitoring these interactions is crucial for understanding the potential direction of Arcutis Biotherapeutics, Inc. (ARQT).

In addition to understanding who is investing in Arcutis Biotherapeutics, Inc. (ARQT), it's equally important to understand why. Investment rationales can vary widely:

• Long-Term Growth Prospects: Investors may be optimistic about Arcutis Biotherapeutics, Inc. (ARQT)'s pipeline of drug candidates and their potential to generate revenue in the future.
• Market Position: A strong market position in a particular therapeutic area can attract investors seeking stable, long-term returns.
• Acquisition Potential: Arcutis Biotherapeutics, Inc. (ARQT) might be an attractive acquisition target for larger pharmaceutical companies, driving investment based on speculation of a buyout.

Understanding these motivations can provide a deeper context for investment decisions and potential future actions.

For more insights into Arcutis Biotherapeutics, Inc. (ARQT)'s mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of Arcutis Biotherapeutics, Inc. (ARQT).

Arcutis Biotherapeutics, Inc. (ARQT) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Arcutis Biotherapeutics, Inc. (ARQT). This analysis encompasses recent market behavior, major shareholder activity, and analyst perspectives to provide a comprehensive view of the company's financial standing.

Recent market data indicates the stock price of Arcutis Biotherapeutics was $12.96 as of April 16, 2025. Recent trading saw the stock experience a day's volatility with a 5.9% upside and a 2.0% downside. Over the past year, the stock has shown considerable fluctuation, with a 52-week high of $17.75 and a low of $6.99.

The stock market has reacted to company announcements and developments. For instance, in early April 2025, Arcutis Biotherapeutics' shares jumped 10.8% following an agreement with Padagis to stay patent litigation related to Zoryve. Similarly, after Arcutis Biotherapeutics reported its fourth-quarter 2024 earnings, which beat expectations, the stock rose by 7.95% in aftermarket trading, closing at $13.17.

Several institutional investors hold significant positions in Arcutis Biotherapeutics:

• Jennison Associates LLC: 10.40%
• Suvretta Capital Management, LLC: 9.61%
• Rubric Capital Management LP: 9.24%
• BlackRock Inc.: 7.71%
• Polar Capital Holdings PLC: 6.22%
• Vanguard Group Inc.: 5.43%

Increased search interest from Indian investors reflects growing global attention toward Arcutis Biotherapeutics. Search interest has increased by 86% in the last 30 days.

Analysts' recommendations provide further insight into the stock's potential. A consensus of 76% of analysts recommend a 'Buy' rating for Arcutis Biotherapeutics, while 23% suggest 'Hold,' and 0% recommend to 'Sell'.

Here is a summary of recent analyst ratings:

These ratings reflect a generally positive outlook, with price targets ranging from $15.00 to $21.00.

Several analysts are actively covering Arcutis Biotherapeutics, including:

• Tyler Van Buren (Cowen)
• Chris Shibutani (Goldman Sachs)
• Seamus Fernandez (Guggenheim)
• Kambiz Yazdi (Jefferies)
• Uy Ear (Mizuho Securities)
• Vikram Purohit (Morgan Stanley)
• Serge Belanger (Needham & Co.)

Recent insider trading activity shows a mixed sentiment. Over the last three months, insiders have bought 329,000 shares and sold 179,853 shares. This results in a net activity of 149,147 shares bought. However, over the last 12 months, insiders have bought 556,816 shares and sold 571,976 shares, resulting in a net activity of -15,160 shares.

Short interest data provides insights into market sentiment. As of March 31, 2025, the short interest was 14,629,541 shares, with an average share volume of 2,964,711.

Arcutis Biotherapeutics reported strong Q4 2024 financial results, with ZORYVE net product revenue reaching $69.4 million, a 413% increase year-over-year and 55% increase quarter-over-quarter. Full-year 2024 ZORYVE revenue was $166.5 million, up 471% from 2023. The company expects to reach cash flow break-even in 2026 and had $226 million in cash as of December 31, 2024.

Furthermore, Arcutis Biotherapeutics granted 27,000 restricted stock units to three newly hired employees on March 3, 2025, and 35,000 restricted stock units to five newly hired employees on April 1, 2025. These grants, under the 2022 Inducement Plan, vest over four years, contingent upon continued employment.

For more insights into the company's strategic direction, explore: Mission Statement, Vision, & Core Values of Arcutis Biotherapeutics, Inc. (ARQT).